Britain and America have reached a significant bilateral deal that will keep zero duties on British medicine products entering the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase spending on drugs through the public health system. This pledge secures that import taxes on these crucial exports will be held at nothing for a timeframe of 36 months.
This agreement follows recent threats to dramatically increase tariffs on patented drug products, with potential rates mentioned up to 100%.
"This arrangement between the UK strengthens the worldwide climate for cutting-edge drugs and establishes much-needed equity to transatlantic drug exports," an announcement said.
Economic Impact
Pharmaceuticals represent one of the Britain's largest exports to the US, which is by far the largest destination for leading British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to the third quarter, the UK sold medicines worth £11.1bn to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This guarantee protects jobs, increases capital expenditure and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, refunds were more than 20%.
Recent Tensions
The pact takes place against a long-running dispute between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that American customers were paying several times more for the same drugs than patients in the other developed nations.
In recent months, several large manufacturing plans in the UK have been paused or cancelled, while substantial expansions have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
